Protein kinase C (PKC)
Family in Homo sapiens that 5 drugs act on.
- Drugs that act on it: 5
- Approved: 1
- In phases 1 to 3: 4
- Sponsors: 3
- Genes: 11
Who is on it, and how far along
Every drug ChEMBL records acting on PRKCA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- GSK120%
- Novartis Pharmaceuticals120%
- ReBio Pharma120%
| Midostaurin | Approved | Novartis Pharmaceuticals | Small molecule | Inhibitor | 16 |
| Sotrastaurin | Phase 2 | ReBio Pharma | Small molecule | Inhibitor | 1 |
| UCN-01 | Phase 2 | — | Small molecule | Inhibitor | 0 |
| CEP-2563 | Phase 1 | — | Small molecule | Inhibitor | 0 |
| GSK-690693 | Phase 1 | GSK | Small molecule | Inhibitor | 0 |
| Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML) | Midostaurin | Phase 3 | Not yet recruiting | University Hospital, Toulouse | Nov 19, 2026 |
| Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma | Sotrastaurin | Phase 1 / Phase 2 | Not yet recruiting | ReBio Pharma | Aug 5, 2026 |
| Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia | Midostaurin | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Bordeaux | Jul 24, 2026 |
| Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | Midostaurin | — | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | May 7, 2026 |
| FLT3-ITD Targeted Therapy in Fit AML Patients | Midostaurin | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | Feb 23, 2026 |
| Revumenib in Combination With 7+3 + Midostaurin in AML | Midostaurin | Phase 1 | Recruiting | Richard Stone, MD | Mar 15, 2024 |
| Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients | Midostaurin | Phase 1 | Recruiting | University Hospital Tuebingen | Feb 9, 2024 |
| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) | Midostaurin | — | Recruiting | Acute Leukemia French Association | Mar 2, 2021 |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | Midostaurin | Phase 1 / Phase 2 | Recruiting | Technische Universität Dresden | May 12, 2020 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093867, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets